A pivotal study of Ad-RTS-hIL-12 + veledimex for recurrent glioblastoma multiforme (GBM)

Trial Profile

A pivotal study of Ad-RTS-hIL-12 + veledimex for recurrent glioblastoma multiforme (GBM)

Suspended
Phase of Trial: Phase III

Latest Information Update: 10 May 2018

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 10 May 2018 According to a ZIOPHARM Oncology media release, the company is pausing plans for its pivotal randomized control trial for Ad-RTS-hIL-12 plus 20mg dose of veledimex for the treatment of rGBM, as they are making progress in resolving technical requirements related to Chemistry and Manufacturing Control (CMC).
    • 10 May 2018 Status changed from planning to suspended, According to a ZIOPHARM Oncology media release.
    • 09 Jan 2018 According to a ZIOPHARM Oncology media release, the company will initiate the trial in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top